Stoke Therapeutics, Inc.
STOK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $596 | $231 | $359 | $881 |
| - Cash | $128 | $191 | $114 | $145 |
| + Debt | $5 | $2 | $2 | $2 |
| Enterprise Value | $473 | $42 | $248 | $738 |
| Revenue | $37 | $9 | $12 | $0 |
| % Growth | 316.3% | -29.2% | – | – |
| Gross Profit | $37 | $9 | $12 | $0 |
| % Margin | 100% | 100% | 100% | – |
| EBITDA | -$99 | -$112 | -$103 | -$85 |
| % Margin | -271.4% | -1,279.1% | -828.8% | – |
| Net Income | -$89 | -$105 | -$101 | -$86 |
| % Margin | -243.4% | -1,192.5% | -814.7% | – |
| EPS Diluted | -1.65 | -2.38 | -2.6 | -2.34 |
| % Growth | 30.7% | 8.5% | -11.1% | – |
| Operating Cash Flow | -$87 | -$81 | -$32 | -$67 |
| Capital Expenditures | -$0 | -$2 | -$4 | -$1 |
| Free Cash Flow | -$87 | -$83 | -$36 | -$68 |